2026/06/05 by Karisa C Schreck, Macarena I de la Fuente, Mary Jane Lim Fat +21 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Brain Metastases and Treatment #Glioma Diagnosis and Treatment #Melanoma and MAPK Pathways
paper · doi:10.1093/neuonc/noag135
openalex publication_date 2026/06/05 · openalex created_date 2026/06/10 · openalex updated_date 2026/07/22
Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.